Media Center
Press Releases

Press Releases

21 Jul 16
Despite 330 Products in the Pipeline, Stem Cell Therapies Still Face Commercial Challenges, says GBI Research

While steady progress in clinical research and increasing evidence of product effectiveness are significant driving factors for growth in the stem cell therapies market, a number of obstacles remain before they become widely commercially viable, according to business intelligence provider GBI Research.

Read post
19 Jul 16
Asia-Pacific Osteoporosis Market Set to Reach $7.7 Billion by 2022 as Awareness Increases, says GBI Research

The osteoporosis market in the Asia-Pacific (APAC) region, which covers India, China, Australia, South Korea and Japan, is set to grow from $4.5 billion in 2015 to $7.7 billion in 2022, at a compound annual growth rate of 7.8%, according to business intelligence provider GBI Research.

Read post
30 Jun 16
Global Urological Cancers Market Will Double to $35.9 billion by 2022, says GBI Research

The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%, according to business intelligence provider GBI Research.

Read post
28 Jun 16
Innovative First-in-Class Products Comprise 30% of Diabetes Complications Pipeline, says GBI Research

The diabetes complications space has high potential for changes and improvements as it becomes more diverse, with 30% of diabetic complication products in active development considered to be first-in-class, according to business intelligence provider GBI Research.

Read post
21 Jun 16
Leukemia Has Largest Pipeline and Most First-in-Class Innovation in Hematological Cancers Space, says GBI Research

Of the three major indications within hematological cancer, namely leukemia, lymphoma and myeloma, leukemia has the largest pipeline, with 798 products in active development, while lymphoma has 552 and myeloma has 396, according to business intelligence provider GBI Research.

Read post